Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced the pricing of an underwritten ...
The following slide deck was published by CytomX Therapeutics, Inc. in conjunction with this event. For further details see: CytomX Therapeutics (CTMX) Presents at J.P. Morgan Healthcare Conference 2021 - Slideshow
CytomX Therapeutics (CTMX) commences an underwritten public offering of $75M of its common stock.Company expects to grant the underwriters an option to purchase up to an additional $11.25M shares. Actual size or terms of the offering are yet to be finalised.Company expects to use the net...
CytomX Therapeutics (CTMX) announces that it has commenced an underwritten public offering of $75M of its common stock.In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additional $11.25M of its common stock at the public offering price, less unde...
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announ...
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announ...
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announ...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announ...
CytomX Therapeutics, Inc. (CTMX) Q3 2020 Earnings Conference Call November 5, 2020 17:00 ET Company Participants Stephanie Ascher - Investor Relations Sean McCarthy - President & Chief Executive Officer Amy Peterson - Chief Financial Officer Carlos Campoy - Senior Vice President & Chi...
Image source: The Motley Fool. CytomX Therapeutics, Inc. (NASDAQ: CTMX) Q3 2020 Earnings Call Nov 5, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: CytomX Therapeutics, Inc. (CTMX) Q3 2020 Earnings Call Transcript ...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...